Themes
Business
Talent
At the park
Communities
Jobs & internships
Events
News
Contact
The Leiden Early Drug Discovery & Development (LED3) network is a collaboration between Leiden University’s Institute of Biology (IBL), Leiden Institute of Chemistry (LIC), and the Leiden Academic Centre for Drug Research (LACDR).
LED3 drives the discovery of innovative drug targets, molecules, and concepts to develop safer, more effective treatments for diseases like cancer, cardiovascular, neurodegenerative, and infectious conditions.
By combining expertise across early drug discovery stages, LED3 enhances understanding of molecular and cellular interactions, advancing novel approaches to drug development.
Located near the Leiden Bio Science Park and LUMC, LED3 partners with academia and industry to accelerate drug discovery and development.
Join a lecture by Professor Kim Lewis from Boston, USA.
Professor Lewis is a University Distinguished Professor and Director of the Antimicrobial Discovery Center at Northeastern University in Boston. His research focuses on antimicrobial drug tolerance and drug discovery, particularly the study of persister cells—dormant variants of regular cells that are tolerant to antibiotics—and uncultured bacteria.
This lecture offers a unique opportunity to gain insights into the role of natural products in antibiotic development and the challenges associated with combating antibiotic tolerance.